Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
暂无分享,去创建一个
P. L. Bergsagel | S. Trudel | S. Gibson | J. Johnston | D. Spaner | V. Kukreti | C. Leung-Hagesteijn | W. Xu | Christine I. Chen | Zhi Hua Li | Joseph E Brandwein | Z. H. Li | A. Lau | Tiffany A. Hernandez | E. Wei | Harminder K Paul | N. Dave | Harminder Paul | M. Pantoja | Joseph Brandwein | Joseph M. Brandwein | Chungyee Leung-Hagesteijn
[1] A. Berrebi,et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.
[2] Lisa L. Smith,et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. , 2010, Blood.
[3] Walter Kolch,et al. MST Kinases Monitor Actin Cytoskeletal Integrity and Signal via c-Jun N-Terminal Kinase Stress-Activated Kinase To Regulate p21Waf1/Cip1 Stability , 2009, Molecular and Cellular Biology.
[4] B. Escudier,et al. A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma , 2009, Clinical Cancer Research.
[5] L. Tremmel,et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Thomas E. Hughes,et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia , 2009, Haematologica.
[7] Lisa Morrison,et al. Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. , 2009, Blood.
[8] J. Byrd,et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.
[9] Z. Estrov,et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. , 2008, Blood.
[10] Lisa L. Smith,et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Parmiani,et al. Human Lymphocyte Activation Gene-3 Molecules Expressed by Activated T Cells Deliver Costimulation Signal for Dendritic Cell Activation1 , 2008, The Journal of Immunology.
[12] G. O'Neill,et al. Tropomyosins as interpreters of the signalling environment to regulate the local cytoskeleton. , 2008, Seminars in cancer biology.
[13] M. Gordon. Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997 , 2008 .
[14] P. Loehrer. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2008 .
[15] S. Gibson,et al. Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. , 2008, British journal of haematology.
[16] T. Robak,et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] T. Kipps,et al. Lenalidomide Abrogates the Protective Influence of Nurse-Like Cells on Primary Chronic Lymphocytic Leukemia Cells In Vitro. , 2007 .
[18] J. Zeldis,et al. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] K. Schäkel,et al. A Soluble Form of Lymphocyte Activation Gene-3 (IMP321) Induces Activation of a Large Range of Human Effector Cytotoxic Cells , 2007, The Journal of Immunology.
[20] R. Silverman. Viral Encounters with 2′,5′-Oligoadenylate Synthetase and RNase L during the Interferon Antiviral Response , 2007, Journal of Virology.
[21] M. Czuczman,et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Irene Ghobrial,et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. , 2006, Blood.
[23] G. Brittinger,et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. , 2005, Blood.
[24] A. Dalgleish,et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. , 2005, Microvascular research.
[25] G. Wolbring,et al. Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immunomodulatory Drugs , 2003, Journal of Pharmacology and Experimental Therapeutics.
[26] D. Vignali,et al. The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells , 2003, European journal of immunology.
[27] A. Tefferi,et al. Analysis of clonal B‐cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B‐chronic lymphocytic leukaemia , 2001, British journal of haematology.
[28] B. Cheson,et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[29] M. Dréano,et al. Lymphocyte activation gene‐3 induces tumor regression and antitumor immune responses , 1999, European journal of immunology.
[30] P. Haslett,et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.
[31] L. Rassenti,et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. , 1998, The Journal of clinical investigation.
[32] M. Grever,et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.
[33] C. Auffray,et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens , 1992, The Journal of experimental medicine.
[34] T R Fleming,et al. One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.